arrow
É

Émilie Crouchet

universites de strasbourg etablissements associes
H指数:18
被引数:2,337

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole

新型抗精神病药物阿立哌唑对肝细胞癌的化学预防作用

2026-03-010
PRE
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models
2025-11-030
OA
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis

Claudin-1是原发性硬化性胆管炎的介质和治疗靶点

2025-08-200
PREAI
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development

在转分化与程序性细胞死亡启动之间的决策点调控KRAS依赖性胰腺癌的发展

2025-02-190
OA
A patient-derived HCC spheroid system to model the tumor microenvironment and treatment response

一种基于患者来源的HCC类器官系统,用于模拟肿瘤微环境和治疗反应

2025-02-010
OAAI
Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting claudin-1
2024-03-220
PRE
A patient-derived hepatocellular carcinoma multicellular spheroid platform harnessing autologous patient serum to model the tumor microenvironment and treatment response
2024-03-220
PRE
Claudin-1 is a driver and therapeutic target for cholangiocarcinoma
2023-04-140
PRE
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment
2023-02-0125
OAAI
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity
2022-12-2117
OA
Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation
2022-07-089
OA
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
2022-06-2255
OA
Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development

预测长期肝纤维化进展的分子特征,以告知抗纤维化药物的开发

2022-04-0118
OA
Claudin-1 is a therapeutic target for hepatocellular carcinoma
2021-12-010
PRE
A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery
2021-09-1726
OAAI